ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

alisertib

Also written as “Alisertib”, “[^14C]-alisertib” and “Alisertib (MLN8237)”.

Its studies are mostly in Lymphoma · Small Cell Lung Carcinoma · Breast Neoplasms · Ovarian Neoplasms · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.

Drug pageMLN 8237: every studyAll 59 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 28, 201124 company-led studies, 3 open or runningNext primary completion: Oct 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only200 open or runningphase 3since Nov 28, 2011Jul 12, 2007none ahead
Puma Biotechnology33 open or runningphase 2since Sep 27, 2023Sep 27, 2023Oct 30, 2027phase 2 · NCT06095505
Sarah Cannon Research Instituteits history only10 open or runningphase 2since Jul 6, 2014Jul 6, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Puma Biotechnology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2023First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT06095505 · 120 planned · United States
  2. Apr 12, 2024Phase 2 study in Breast NeoplasmsNCT06369285 · 225 planned · United States, Portugal, Spain
  3. Mar 6, 2026Phase 2 study in Small Cell Lung CarcinomaNCT07465757 · 50 planned · United States, France, Poland and more

Ahead

  1. Oct 30, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT06095505
  2. Dec 30, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06369285
  3. Mar 31, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07465757

TargetBeta

AURKA →read by rule
“Serine/threonine-protein kinase Aurora-A inhibitor”ChEMBL 37, by rule

Studies

All 3 Puma Biotechnology leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07465757Small Cell Lung Carcinoma · United States, France, Poland and more2RecruitingMar 31, 202850
NCT06369285Breast Neoplasms · United States, Portugal, Spain2RecruitingDec 30, 2027225
NCT06095505Small Cell Lung Carcinoma · United States2RecruitingOct 30, 2027120

How it is read

Names in the registry

  • “Alisertib”, 23 entries
  • “alisertib”, 2 entries
  • “[^14C]-alisertib”, 1 entry
  • “Alisertib (MLN8237)”, 1 entry
  • “MLN8237 (Alisertib)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.